Putting Patients First Blog
DECEMBER 9, 2024
CMS is proposing setting a 20% coinsurance/equivalent copayment limit for behavioral health services, eliminating cost-sharing for opioid treatment program services, and capping inpatient psychiatric service cost sharing to 100% of Medicare Fee-For-Services levels.
Pharmacy Times
JULY 3, 2025
Pharmacy Times : How does the team ensure smooth transitions from inpatient to outpatient transplant care, particularly regarding medication management? So there were a lot of things. It's not just about, “Oh, let’s give them their nausea medicine,” but let’s make sure we get it to them correctly and in a timely fashion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 16, 2025
Literature suggests a 3% difference in the rate of FN between CSF agents filgrastim (Neupogen; Amgen)/filgrastim biosimilars and pegfilgrastim (Neulasta; Amgen)/pegfilgrastim biosimilars. A retrospective chart review was performed. Forty-four of 88 charts met the inclusion criteria and were evaluated using the Fisher exact test.
pharmaphorum
OCTOBER 1, 2020
Adalimumab – sold by AbbVie as Humira as well as in biosimilar form by companies including Novartis’ Sandoz unit, Amgen and Biogen/Samsung joint venture Bioepis – will be used in the phase 2 AVID-CC study to see if it can prevent progression to respiratory failure in people with coronavirus infections.
Pharmacy Times
JUNE 17, 2025
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Pharmacy Times
JUNE 20, 2025
For effective patient care, we need smart people to design workflows for operationalizing 505(b)(2) drugs, integrating the next biosimilar we have to stock, and managing the compounding of a new hazardous drug. We need people to coordinate and track prior authorizations, write persuasive appeal letters, and keep patients updated.
Pharmacy Times
JUNE 11, 2025
Related Videos Related Content Advertisement June 11th 2025 Perioperative Nivolumab Shows Long-Term EFS, Favorable OS in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2.
Expert insights. Personalized for you.
52 
Let's personalize your content